FDA approval of Vyvgart (efgartigimod alfa-fcab)in generalized myasthenia gravis .- Zai Lab and argenx.
These patients represent approximately 85% of the total gMG population. With this regulatory milestone, Vyvgart is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker.
The approval of Vyvgart is based on results from the global Phase III ADAPT trial, which were published in the July 2021 issue of The Lancet Neurology. The ADAPT trial met its primary endpoint, demonstrating that significantly more anti-AChR antibody positive gMG patients were responders on the MG-ADL scale following treatment with Vyvgart compared with placebo (68% vs. 30%; p<0.0001). responders were defined as having at least a two-point reduction on the mg-adl scale sustained for four or more consecutive weeks during the first treatment cycle..></0.0001).>
See-ARTICLES| VOLUME 20, ISSUE 7, P526-536, JULY 01, 2021 -"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase III trial"; Prof James F Howard Jr, MD Vera Bril, MD, Prof Tuan Vu, MD, Chafic Karam, MD,et al. Published:July, 2021DOI:https://doi.org/10.1016/S1474-4422(21)00159-9,The Lancet Neurology.
Related news and insights
EQRx, Inc. a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase III studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that the European Commission has approved Tavneos (avacopan) in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.
A second Phase III trial evaluating Dupixent (dupilumab), from Sanofi, in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease, met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks in this investigational setting.